Rhenman & Partners Asset Management AB Purchases New Stake in uniQure N.V. $QURE

Rhenman & Partners Asset Management AB purchased a new stake in shares of uniQure N.V. (NASDAQ:QURE) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 79,375 shares of the biotechnology company’s stock, valued at approximately $1,899,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Jones Financial Companies Lllp grew its stake in uniQure by 509.0% in the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 509 shares in the last quarter. CIBC Private Wealth Group LLC purchased a new position in uniQure in the third quarter valued at about $50,000. Torren Management LLC purchased a new position in uniQure in the fourth quarter valued at about $28,000. FNY Investment Advisers LLC grew its stake in uniQure by 76.7% in the third quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 718 shares in the last quarter. Finally, IFP Advisors Inc purchased a new position in uniQure in the fourth quarter valued at about $48,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on QURE shares. Cantor Fitzgerald restated a “neutral” rating and issued a $9.00 target price (down from $55.00) on shares of uniQure in a research note on Monday, March 2nd. Royal Bank Of Canada upgraded uniQure from a “sector perform” rating to an “outperform” rating and boosted their target price for the company from $11.00 to $35.00 in a research note on Monday, March 9th. Wells Fargo & Company upgraded uniQure from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $15.00 to $60.00 in a research note on Monday, March 9th. Stifel Nicolaus set a $28.00 target price on uniQure in a research note on Tuesday, May 5th. Finally, Wolfe Research started coverage on uniQure in a research note on Monday, February 23rd. They issued a “peer perform” rating on the stock. Ten research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $42.83.

Key Stories Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Negative Sentiment: A cluster of insiders sold shares in recent filings, including directors Robert Gut, Madhavan Balachandran, Rachelle Suzanne Jacques, Jack Kaye, Leonard E. Post, Jeremy P. Springhorn, and David D. Meek, along with insider Kylie O’keefe. The transactions totaled a meaningful reduction in ownership across the group, increasing focus on insider confidence. Article: UniQure Rocked by Wave of High-Level Insider Stock Sales
• Neutral Sentiment: Several of the sales were made under pre-arranged Rule 10b5-1 trading plans, which can lessen the bearish signal because the trades may have been scheduled in advance rather than reflecting a sudden change in outlook.
• Neutral Sentiment: The stock has already been trending above its 50-day and 200-day moving averages, so some of the selling may simply reflect profit-taking after a strong move rather than a deterioration in the company’s fundamentals.

Insider Activity at uniQure

In other news, Director Rachelle Suzanne Jacques sold 1,993 shares of the company’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $27.06, for a total transaction of $53,930.58. Following the completion of the sale, the director owned 33,903 shares in the company, valued at approximately $917,415.18. This represents a 5.55% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Jack Kaye sold 1,993 shares of the company’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $27.06, for a total value of $53,930.58. Following the sale, the director owned 25,996 shares of the company’s stock, valued at approximately $703,451.76. This trade represents a 7.12% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 85,817 shares of company stock worth $2,232,383 in the last 90 days. Insiders own 4.65% of the company’s stock.

uniQure Stock Performance

QURE opened at $27.57 on Friday. The company has a market cap of $1.74 billion, a PE ratio of -7.92 and a beta of 0.98. The stock has a 50-day moving average of $22.52 and a 200-day moving average of $21.80. uniQure N.V. has a 52-week low of $8.73 and a 52-week high of $71.50. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.40 and a current ratio of 10.40.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.03. The company had revenue of $3.56 million during the quarter, compared to the consensus estimate of $5.21 million. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%. As a group, equities research analysts forecast that uniQure N.V. will post -3.64 earnings per share for the current fiscal year.

uniQure Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.